

# Evaluating potential impact of monoamine oxidase A missense L32S on the function of the enzyme monoamine oxidase A using *in silico* prediction tools and molecular modeling

Jared Laughlin<sup>1</sup>, Cynthia L Stenger<sup>2§</sup>, Hanna J Jefcoat<sup>3</sup>

<sup>1</sup>Chemistry and Physics, University of North Alabama, Florence, Alabama, United States


<sup>2</sup>Mathematics, University of North Alabama, Florence, Alabama, United States

<sup>3</sup>Biology, University of North Alabama, Florence, Alabama, United States

<sup>§</sup>To whom correspondence should be addressed: clstenger@una.edu

## Abstract

Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that affects 6-7% of people worldwide (Wilcutt, 2012). MAOA is a gene that encodes monoamine oxidase A, an enzyme responsible for the regulation and metabolism of monoamines thought to be associated with ADHD. This study investigates a leucine to serine swap at amino acid position 32 in FAD-binding domain of the enzyme monoamine oxidase A. Results from *in silico* prediction tools and molecular dynamics modeling provide evidence to support pathogenicity of the L32S missense variant of monoamine oxidase A.



**Figure 1. Characterization of L32S:**

**A)** Analyzed pathogenicity using *in silico* predictors CADD, PolyPhen-2, and MutPred2 (Schubach et al., 2024; Adzhubei et al., 2010; Pejaver et al., 2020). All scores were normalized for comparison to show predicted pathogenicity of a known benign variant, the VUS being studied, and a known pathogenic variant. L32S is ranked as more highly pathogenic than the known pathogenic variant with all tools except CADD. **B)** YASARA homology modeling of monoamine oxidase A with highlighted swap. The legend indicates the functional domains of monoamine oxidase A. Note that L32 is located in the FAD-binding domain. **C)** Chart showing the root-mean-square deviation (RMSD) of L32S variant and wildtype monoamine oxidase A over a 20000 ps simulation. The first 10000 ps are considered equilibration and were not considered for analysis. (Gay et al., 2024) Note the stark divergence between the wildtype protein and the L32S variant **D)** ConSurf model of monoamine oxidase A

4/10/2025 - Open Access

(Yariv et al., 2023; Landau et al., 2005). The pink regions are more highly conserved than the blue regions. L32 is shown in a deep magenta color, indicating its high conservation grade of 9/9.

## Description

Monoamine oxidase A catalyzes the oxidative deamination of monoamines. Monoamine oxidase A is expressed alongside monoamine oxidase B in most human tissues. It's most abundant in the small intestine but is also expressed in the brain. Monoamine oxidase A is expressed in catecholaminergic neurons, where it metabolizes catecholamines such as norepinephrine and dopamine (Shih et al., 2004). Monoamine oxidase A catalyzes the first step in the processes of metabolism and excretion of catecholamines. Treatments for attention-deficit hyperactivity disorder (ADHD) target catecholamine systems in the brain, and ADHD is thought to be related to dysfunction in these catecholamine systems (Arnsten et al., 2011). Since monoamine oxidase A is expressed in these same neural circuits and impacts catecholamine concentrations in neurons, a variant in monoamine oxidase A could potentially contribute to the pathophysiology of ADHD.

One example of how monoamine oxidase A could contribute to the pathophysiology of ADHD is related to the high prevalence of substance use disorders (SUDs) in individuals with ADHD. Individuals with ADHD are much more likely to suffer from SUDs than non-ADHD individuals (Choi et al., 2022). SUDs are mediated by dopaminergic activity in the nucleus accumbens (Gardner, 2011). This is especially interesting as monoamine oxidase A is very highly expressed in the nucleus accumbens, where it degrades monoamines like dopamine (Kolla et al., 2020). Despite their reinforcing properties, catecholaminergic drugs used to treat ADHD reduce the risk of developing SUDs in individuals with ADHD and do not worsen existing SUDs (Hammerness et al., 2017; Levy et al., 2014; Wilens et al., 2003).

The leucine to serine swap at amino acid position 32 (L32S) has higher predicted pathogenicity scoring than both the selected benign and pathogenic variants for PolyPhen-2, and MutPred2, and L32S had a higher predicted pathogenicity score than the selected benign variant for CADD (Figure 1A) (Schubach et al., 2024; Adzhubei et al., 2010; Pejaver et al., 2020). The residue found in position 32 is very highly conserved according to the ConSurf server, with a conservation grade of 9/9 (Yariv et al., 2023; Landau et al., 2005). The residue is also located in the flavin adenine dinucleotide (FAD)-binding domain (Figure 1B). FAD is a redox active cofactor associated with monoamine oxidase A. The non-polar to polar swap from leucine to serine within the FAD-binding domain may alter the binding of this coenzyme to monoamine oxidase A, due to the abundance of polar bonds in the structure of FAD (National Center for Biotechnology Information, 2025). This variant also involves swapping a helix former, leucine, to a helix breaker, serine, on an alpha helix (Lewis, 1970). This can compromise the structural integrity of the protein and significantly alter the interaction between monoamine oxidase A and its environment. It is not currently known what structural effects this could have on the binding pocket of the enzyme. Although the swap occurred at position 32, the model shows consequential shifting throughout the sequence. The RMSD (Figure 1C) shows a stark divergence between the wildtype and the L32S variant.

## Methods

MAOA is one of the few genes known to be associated with metabolism of catecholamines. Monoamine oxidase A was chosen for study because of the wide variety of pharmaceutical drugs known to interact with this enzyme, opening up the possibility of future medical applications of this research. A variant of unknown significance (VUS) from MAOA L32S was chosen by comparing normalized scores from various pathogenicity predictors (Figure 1A). Using the ConSurf server, L32 was found to be highly evolutionarily conserved when compared to its homologues (Yariv et al., 2023; Landau et al., 2005). Slow homology models of the wildtype and variant proteins were constructed from a FASTA (P21397) sequence retrieved from UniProt. Using these homology models, molecular dynamics simulations were run using YASARA protein modeling to assess how the variant affects protein functionality. Molecular dynamics simulations model the movement of a protein in an aqueous environment over a period of 20000 picoseconds.

## References

Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. 2010. A method and server for predicting damaging missense mutations. *Nat Methods* 7(4): 248-9. PubMed ID: [20354512](#)

Arnsten AF, Pliszka SR. 2011. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. *Pharmacol Biochem Behav* 99(2): 211-6. PubMed ID: [21295057](#)

Choi WS, Woo YS, Wang SM, Lim HK, Bahk WM. 2022. The prevalence of psychiatric comorbidities in adult ADHD compared with non-ADHD populations: A systematic literature review. *PLoS One* 17(11): e0277175. PubMed ID: [36331985](#)

4/10/2025 - Open Access

Gardner EL. 2011. Addiction and brain reward and antireward pathways. *Adv Psychosom Med* 30: 22-60. PubMed ID: [21508625](#)

Gay C, Watford S, Johnson EB. 2024. Comparison of Variants of Uncertain Significance in Three Regions of the Human Glucokinase Protein Using In Vitro and In Silico Analyses. *Cureus* : 10.7759/cureus.68638. DOI: [10.7759/cureus.68638](#)

Hammerness P, Petty C, Faraone SV, Biederman J. 2017. Do Stimulants Reduce the Risk for Alcohol and Substance Use in Youth With ADHD? A Secondary Analysis of a Prospective, 24-Month Open-Label Study of Osmotic-Release Methylphenidate. *J Atten Disord* 21(1): 71-77. PubMed ID: [23264367](#)

Kolla NJ, Bortolato M. 2020. The role of monoamine oxidase A in the neurobiology of aggressive, antisocial, and violent behavior: A tale of mice and men. *Prog Neurobiol* 194: 101875. PubMed ID: [32574581](#)

Landau M, Mayrose I, Rosenberg Y, Glaser F, Martz E, Pupko T, Ben-Tal N. 2005. ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures. *Nucleic Acids Res* 33(Web Server issue): W299-302. PubMed ID: [15980475](#)

Levy S, Katusic SK, Colligan RC, Weaver AL, Killian JM, Voigt RG, Barbaresi WJ. 2014. Childhood ADHD and risk for substance dependence in adulthood: a longitudinal, population-based study. *PLoS One* 9(8): e105640. PubMed ID: [25162629](#)

Lewis PN, G[unk]o N, G[unk]o M, Kotelchuck D, Scheraga HA. 1970. Helix Probability Profiles of Denatured Proteins and Their Correlation with Native Structures. *Proceedings of the National Academy of Sciences* 65: 810-815. DOI: [10.1073/pnas.65.4.810](#)

National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 643975, Flavin-Adenine Dinucleotide. Retrieved January 31, 2025 from <https://pubchem.ncbi.nlm.nih.gov/compound/Flavin-Adenine-Dinucleotide>.

Pejaver V, Urresti J, Lugo-Martinez J, Pagel KA, Lin GN, Nam HJ, et al., Radivojac P. 2020. Inferring the molecular and phenotypic impact of amino acid variants with MutPred2. *Nat Commun* 11(1): 5918. PubMed ID: [33219223](#)

Schubach M, Maass T, Nazaretyan L, Röner S, Kircher M. 2024. CADD v1.7: using protein language models, regulatory CNNs and other nucleotide-level scores to improve genome-wide variant predictions. *Nucleic Acids Res* 52(D1): D1143-D1154. PubMed ID: [38183205](#)

Shih JC, Chen K. 2004. Regulation of MAO-A and MAO-B gene expression. *Curr Med Chem* 11(15): 1995-2005. PubMed ID: [15279563](#)

Thomas PD, Ebert D, Muruganujan A, Mushayahama T, Albou LP, Mi H. 2021. PANTHER: Making genome-scale phylogenetics accessible to all. *Protein Science* 31: 8-22. DOI: [10.1002/pro.4218](#)

Wilens TE, Faraone SV, Biederman J, Gunawardene S. 2003. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. *Pediatrics* 111(1): 179-85. PubMed ID: [12509574](#)

Willcutt EG. 2012. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. *Neurotherapeutics* 9(3): 490-9. PubMed ID: [22976615](#)

Yariv B, Yariv E, Kessel A, Masrati G, Chorin AB, Martz E, et al., Ben-Tal N. 2023. Using evolutionary data to make sense of macromolecules with a "face-lifted" ConSurf. *Protein Sci* 32(3): e4582. PubMed ID: [36718848](#)

**Funding:** This work is supported by the National Science Foundation under Grant Number 2120918. Any opinions, findings, conclusions, or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.

**Author Contributions:** Jared Laughlin: writing - original draft, investigation, methodology, conceptualization, data curation, formal analysis, visualization. Cynthia L Stenger: project administration, supervision, writing - review editing. Hanna J Jefcoat: writing - review editing.

**Reviewed By:**

**History:** Received November 12, 2024 **Revision Received** March 11, 2025 **Accepted** March 28, 2025 **Published Online** April 10, 2025

**Copyright:** © 2025 by the authors. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

---

4/10/2025 - Open Access

**Citation:** Laughlin J, Stenger CL, Jefcoat HJ. 2025. Evaluating potential impact of monoamine oxidase A missense L32S on the function of the enzyme monoamine oxidase A using *in silico* prediction tools and molecular modeling. microPublication Biology. [10.17912/micropub.biology.001414](https://doi.org/10.17912/micropub.biology.001414)